Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

GcgR antagonist enhances functional beta-cell mass and glycemic control in type 1 diabetes

March 4, 2021

Ascendis initiates phase III trial of TransCon PTH for hypoparathyroidism

March 4, 2021

Atherosclerosis precedes clonal hematopoiesis

March 4, 2021

Movement strengthens bones, and immunity

March 4, 2021

Pandion Therapeutics develops bispecific PD-1, MADCAM1 antibody for type 1 diabetes

March 3, 2021

FDA approves Nulibry for molybdenum cofactor deficiency type A

March 1, 2021

Lilly divulges new NNMT inhibitors

March 1, 2021

Osteoclast recycling reveals formation of new cell type that has key role in osteoporosis

March 1, 2021

Pilot trial of lentivirus-mediated enzyme gene therapy for the treatment of Fabry disease

Feb. 26, 2021

First patient dosed in phase III study of eftansomatropin alfa in China

Feb. 26, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...